^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    BIOMARKER:

    FCGR3A 158V

    i
    Other names: FCGR3A, Fc Fragment Of IgG Receptor IIIa, Low Affinity Immunoglobulin Gamma Fc Region Receptor III-A, Fc Fragment Of IgG Low Affinity IIIa Receptor (CD16a), IgG Fc Receptor III-2, Fc-Gamma RIII-Alpha, CD16a Antigen, FCGR3, CD16A, IGFR3, FCG3, Low Affinity Immunoglobulin Gamma Receptor III-A Fc Fragment 3, Fc Fragment Of IgG Low Affinity IIIa Receptor For (CD16), Fc Fragment Of IgG Low Affinity III Receptor For (CD16), Immunoglobulin G Fc Receptor III, Fc-Gamma Receptor III-2 (CD 16), Neutrophil-Specific Antigen NA, Fc-Gamma Receptor IIIb (CD16), Fc Gamma Receptor III-A, Fc Gamma Receptor IIIa, Fc-Gamma RIIIa, Fc-Gamma RIII, FcgammaRIIIA, FCGRIII, FCRIIIA, FcRIIIa, FCR-10, FCRIII, FcR-10, FcRIII, IMD20, CD16
    Entrez ID:
    2214
    Related biomarkers:
    Mutation
    over1year
    Impact of HLA Class I Antigen, Killer Inhibitory Receptor, and FCGR3A Genotypes on Breast Cancer Susceptibility and Tumor Stage. (PubMed, Curr Mol Med)
    Our findings suggest that in the development of BC probably exists a disorder of the NK innate immunity influenced by KIR/HLA-C gene content and FCGR3A-158 polymorphisms and that the combined analysis of these biomarkers might help predict genetic risk scores for tailored screening of BC patients in therapy.
    Journal
    |
    FCGR3A (Fc Fragment Of IgG Receptor IIIa) • KIR2DS4 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Short Cytoplasmic Tail 4) • HLA-C (Major Histocompatibility Complex, Class I, C) • KIR2DL1 (Killer Cell Immunoglobulin Like Receptor, Two Ig Domains And Long Cytoplasmic Tail 1)
    |
    FCGR3A 158V